SCHEMBL10134577

SCHEMBL10134577

COc1c(/C=C/c2ccc(N)cc2)cc(-c2ncc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.51
CYP19A1 P11511 9/20 0.40
ADRA2A P08913 2/20 0.39
ADRA2C P18825 2/20 0.39
ADRA1D P25100 2/20 0.39
ADRA1A P35348 2/20 0.39
ADRA1B P35368 2/20 0.39
NQO2 P16083 2/20 0.37
TNFRSF1A P19438 2/20 0.33
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32
TUBA4A P68366 1/20 0.32
TUBB4B P68371 1/20 0.32
TUBB3 Q13509 1/20 0.32
TUBB2A Q13885 1/20 0.32
TUBB8 Q3ZCM7 1/20 0.32
TUBA3E Q6PEY2 1/20 0.32
TUBA1A Q71U36 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2491321 0.85 CYP3A4 (0.72) CYP3A4ADRA2AADRA2CADRA1DADRA1A
SCHEMBL2491324 0.85 CYP3A4 (0.72) CYP3A4ADRA2AADRA2CADRA1DADRA1A
SCHEMBL10135112 0.84 CYP3A4 (0.45) CYP3A4CYP19A1NQO2TNFRSF1ATUBB4A
SCHEMBL2129692 0.82 CYP3A4 (0.73) CYP3A4CYP19A1NQO2TNFRSF1ATUBB4A
SCHEMBL1764738 0.80 CYP3A4 (0.64) CYP3A4ADRA2AADRA2CADRA1DADRA1A
SCHEMBL6832451 0.79 CYP3A4 (0.52) CYP3A4CYP19A1NQO2TNFRSF1ATUBB4A
SCHEMBL6832645 0.78 CYP3A4 (0.51) CYP3A4CYP19A1ADRA2AADRA2CADRA1D
SCHEMBL6832521 0.78 CYP3A4 (0.54) CYP3A4CYP19A1NQO2TNFRSF1ATUBB4A
SCHEMBL6832450 0.78 CYP19A1 (0.34) CYP3A4CYP19A1NQO2MEN1NPC1
SCHEMBL6832649 0.78 CYP3A4 (0.51) CYP3A4CYP19A1NQO2TNFRSF1ATUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS RFC1, RRP1B, RRBP1 CYP3A4 978/4885CYP19A1 776/4885ADRA2A 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.